Cancer research is undergoing a major paradigm shift in which scientists and doctors are increasingly able to use genetic information to personalize treatments for cancer patients.  At the annual meeting of the American Society of Clinical Oncology in June, national leaders, including seventeen Damon Runyon Clinical Investigators, presented the results of promising studies involving new, targeted therapies that are transforming cancer treatment. 

Speaking to the Wall Street Journal on this shift in the world of cancer research, Dr. John Mendelsohn, Damon Runyon alumnus and President of Houston’s MD Anderson Cancer Center, said “A pattern is developing at an accelerated pace where we are able to match genetic information about a tumor to a new agent and get results.”  In short, scientists are better able to match treatments to individual patients.

> Read the whole post: “A Tipping Point in Cancer Research”